Recently, Hengrui Pharmaceuticals' subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received a Notice of Approval for Clinical Trial of Drugs approved by the State Drug Administration, which approved HRS-7249 Injection, a Class 1 new drug, to carry out clinical trials for the treatment of hyperlipidemia. Upon inquiry, no similar products have been approved for marketing at home and abroad for the time being.

Hypertriglyceridemia (HTG) is a common type of dyslipidemia. Epidemiologic studies have shown that HTG is one of the risk factors for atherosclerotic cardiovascular disease (ASCVD) and acute pancreatitis, and is clearly associated with overweight/obesity, insulin resistance/type 2 diabetes mellitus, non-alcoholic fatty liver disease, and chronic kidney disease.

Currently, triglyceride-lowering drugs often used in clinical practice have limited reduction of triglycerides and have adverse effects such as hepatic and renal impairment, increased risk of atrial fibrillation, and decreased insulin sensitivity, and safer and more effective drugs are needed for the clinical treatment of HTG.

HRS-7249 injection is a Class 1 innovative drug independently developed by the company. Non-clinical efficacy studies showed that HRS-7249 can exert efficient and long-lasting triglyceride (TG) lowering effects in vivo. The non-clinical safety evaluation study showed that HRS-7249 has low off-target risk and good safety.

https://mp.weixin.qq.com/s?__biz=MzU4Njc2Njc0NA==&mid=2247521473&idx=2&sn=9ba9803b614a2575422147e4746633d4&chksm=fdf49436ca831d20a50b01958f0f0f2a621ea690219d2e56dce2e8da06fed03a3cd736e280b6&mpshare=1&scene=1&srcid=0705QtPC6Ia6pCj0glsIZo89&sharer_shareinfo=e081340ec2413a9c9fee2e45b2546abb&sharer_shareinfo_first=e081340ec2413a9c9fee2e45b2546abb#rd